Inventor · disambiguated record
Christian Hinderer
Also filed as: HINDERER CHRISTIAN
15 granted patents·34 pending applications·24 citations·filing 2013–2025
89Inventor score
Files withUNIV PENNSYLVANIA49
Top patents by PatentIndex Score
49 records- 0190US11578341B2Compositions useful in treatment of spinal muscular atrophyUNIV PENNSYLVANIA·Filed 2018·Granted Feb 14, 2023·4 cites·14 claims
- 0290US10780182B2Methods and compositions for treating metastatic breast cancer and other cancers in the brainUNIV PENNSYLVANIA·Filed 2015·Granted Sep 22, 2020·7 cites·28 claims
- 0387US11819539B2Gene therapy for treating Mucopolysaccharidosis type IIUNIV PENNSYLVANIA·Filed 2018·Granted Nov 21, 2023·2 cites·30 claims
- 0486US11253612B2Gene therapy for treating mucopolysaccharidosis type IIUNIV PENNSYLVANIA·Filed 2017·Granted Feb 22, 2022·2 cites·24 claims
- 0586US11135313B2Intrathecal administration of adeno-associated-viral vectors for gene therapyUNIV PENNSYLVANIA·Filed 2016·Granted Oct 5, 2021·4 cites·8 claims
- 0685US9770011B2Veterinary composition and methods for non-surgical neutering and castrationUNIV PENNSYLVANIA·Filed 2013·Granted Sep 26, 2017·4 cites·20 claims
- 0781US2024024510A1Gene therapy for treating mucopolysaccharidosis type iUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 0880US12428653B2Gene therapy for ceroid lipofuscinosesUNIV PENNSYLVANIA·Filed 2022·Granted Sep 30, 2025·0 cites·47 claims
- 0979US2025345402A1Gene therapy for treating mucopolysaccharidosis type iiUNIV PENNSYLVANIA·Filed 2025·Application pending·0 cites
- 1078US2024016903A1Gene therapy for treating mucopolysaccharidosis type iiUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1177US11117942B2AAV-EPO for treating companion animalsUNIV PENNSYLVANIA·Filed 2016·Granted Sep 14, 2021·1 cites·20 claims
- 1276US2024277871A1Methods and compositions for treating metastatic breast cancer and other cancers in the brainUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1374US2024307511A1Aav9-mediated gene therapy for treating mucopolysaccharidosis type iUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1473US2023265459A1Compositions Useful in Treatment of Spinal Muscular AtrophyUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1571US2024009327A1Gene therapy for mucopolysaccharidosis iiibUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1667US2025186613A1Viral vectors encoding glp-2 receptor agonist fusions and uses thereof in treating short bowel syndromeUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1767US2025171515A1Aav vectors for delivery of glp-1 receptor agonist fusionsUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1867US2025186612A1Viral vectors encoding parathyroid hormone fusions and uses thereof in treating hypoparathyroidismUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 1966US11865187B2Methods and compositions for treating metastatic breast cancer and other cancers in the brainUNIV PENNSYLVANIA·Filed 2020·Granted Jan 9, 2024·0 cites·16 claims
- 2066US11723989B2Gene therapy for mucopolysaccharidosis IIIBUNIV PENNSYLVANIA·Filed 2018·Granted Aug 15, 2023·0 cites·28 claims
- 2166US2021228740A1Gene therapy for treating mucopolysaccharidosis type iUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 2266US2022125949A1Gene therapy for treating mucopolysaccharidosis type iiUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 2366US2025388926A1Viral vector genome encoding an insulin fusion proteinUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 2465US2025250326A1Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectorsUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 2564US2024033375A1Compositions useful for treating spinal and bulbar muscular atrophy (sbma)UNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 2664US2024401078A1Compositions useful for treatment of charcot-marie-tooth diseaseUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 2764US2025049949A1Gene therapy for lamin a-associated deficienciesUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 2863US11591614B2Gene therapy for ceroid lipofuscinosesUNIV PENNSYLVANIA·Filed 2018·Granted Feb 28, 2023·0 cites·30 claims
- 2963US10973929B2Gene therapy for treating mucopolysaccharidosis type IUNIV PENNSYLVANIA·Filed 2017·Granted Apr 13, 2021·0 cites·25 claims
- 3063US2022265861A1Adeno-associated viral vectors useful in treatment of spinal muscular atropyUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 3163US2022056090A1Aav-epo for treating companion animalsUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 3262US11890329B2AAV9-mediated gene therapy for treating mucopolysaccharidosis type IUNIV PENNSYLVANIA·Filed 2018·Granted Feb 6, 2024·0 cites·37 claims
- 3362US2021379202A1Intrathecal administration of adeno-associated-viral vectors for gene therapyUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 3462US2024191258A1Compositions useful for treating spinal and bulbar muscular atrophy (sbma)UNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 3561US12416017B2Recombinant adeno-associated virus for treatment of GRN-associated adult-onset neurodegenerationUNIV PENNSYLVANIA·Filed 2020·Granted Sep 16, 2025·0 cites·18 claims
- 3660US2024269328A1Recombinant adeno-associated viruses for lesch-nyhan disorders and uses thereofUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 3760US2023272419A1Canine and feline inducible expression constructs for gene therapy applicationsUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 3859US2023270884A1Compositions useful for treatment of charcot-marie-tooth diseaseUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 3958US2024010699A1Viral vectors encoding canine insulin for treatment of metabolic diseases in dogsUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 4058US2023338478A1Compositions and method of use of mutant ace2 decoy variantsUNIV PENNSYLVANIA·Filed 2023·Application pending·0 cites
- 4157US2023405150A1Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felinesUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 4257US2023372539A1Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseasesUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 4355US2023220069A1Compositions and methods for treatment of gene therapy patientsUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 4454US2018353624A1Adeno-associated viral vectors useful in treatment of spinal muscular atropyUNIV PENNSYLVANIA·Filed 2016·Application pending·0 cites
- 4553US2023190966A1Compositions useful for treating gm1 gangliosidosisUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 4652US2024050521A1Compositions for treating friedreich's ataxiaUNIV PENNSYLVANIA·Filed 2022·Application pending·0 cites
- 4751US2023364264A1Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegenerationUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 4850US12221615B2GLP-1 and use thereof in compositions for treating metabolic diseasesUNIV PENNSYLVANIA·Filed 2016·Granted Feb 11, 2025·0 cites·20 claims
- 4942US2019292250A1Aav-anti-vegf for treating cancer in companion animalsUNIV PENNSYLVANIA·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Christian Hinderer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →